Podcasts about ndd ckd

  • 14PODCASTS
  • 36EPISODES
  • 51mAVG DURATION
  • ?INFREQUENT EPISODES
  • Jan 11, 2023LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about ndd ckd

Latest podcast episodes about ndd ckd

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Jay B. Wish, MD - Novel Strategies for Managing Patients With CKD-Associated Anemia: What Do Health-System Pharmacists Need to Know About HIF-PH Inhibitors?

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 11, 2023 73:05


Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Jay B. Wish, MD - Novel Strategies for Managing Patients With CKD-Associated Anemia: What Do Health-System Pharmacists Need to Know About HIF-PH Inhibitors?

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 11, 2023 26:49


Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Jay B. Wish, MD - Novel Strategies for Managing Patients With CKD-Associated Anemia: What Do Health-System Pharmacists Need to Know About HIF-PH Inhibitors?

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 11, 2023 73:05


Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Jay B. Wish, MD - Novel Strategies for Managing Patients With CKD-Associated Anemia: What Do Health-System Pharmacists Need to Know About HIF-PH Inhibitors?

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 11, 2023 26:49


Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Jay B. Wish, MD - Novel Strategies for Managing Patients With CKD-Associated Anemia: What Do Health-System Pharmacists Need to Know About HIF-PH Inhibitors?

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 11, 2023 73:05


Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Jay B. Wish, MD - Novel Strategies for Managing Patients With CKD-Associated Anemia: What Do Health-System Pharmacists Need to Know About HIF-PH Inhibitors?

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jan 11, 2023 26:49


Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Jay B. Wish, MD - Novel Strategies for Managing Patients With CKD-Associated Anemia: What Do Health-System Pharmacists Need to Know About HIF-PH Inhibitors?

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 11, 2023 26:49


Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Jay B. Wish, MD - Novel Strategies for Managing Patients With CKD-Associated Anemia: What Do Health-System Pharmacists Need to Know About HIF-PH Inhibitors?

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 11, 2023 73:05


Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Rajiv Agarwal, MD, MS - HIF-PH Inhibitors: An Emerging Strategy for Managing Anemia in Patients With Chronic Kidney Disease

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 25, 2021 70:29


Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Rajiv Agarwal, MD, MS - HIF-PH Inhibitors: An Emerging Strategy for Managing Anemia in Patients With Chronic Kidney Disease

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 25, 2021 71:19


Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Rajiv Agarwal, MD, MS - HIF-PH Inhibitors: An Emerging Strategy for Managing Anemia in Patients With Chronic Kidney Disease

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 25, 2021 70:29


Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Rajiv Agarwal, MD, MS - HIF-PH Inhibitors: An Emerging Strategy for Managing Anemia in Patients With Chronic Kidney Disease

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 25, 2021 71:19


Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Rajiv Agarwal, MD, MS - HIF-PH Inhibitors: An Emerging Strategy for Managing Anemia in Patients With Chronic Kidney Disease

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 25, 2021 70:29


Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Rajiv Agarwal, MD, MS - HIF-PH Inhibitors: An Emerging Strategy for Managing Anemia in Patients With Chronic Kidney Disease

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 25, 2021 70:29


Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Rajiv Agarwal, MD, MS - HIF-PH Inhibitors: An Emerging Strategy for Managing Anemia in Patients With Chronic Kidney Disease

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 25, 2021 71:19


Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Rajiv Agarwal, MD, MS - HIF-PH Inhibitors: An Emerging Strategy for Managing Anemia in Patients With Chronic Kidney Disease

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 25, 2021 71:19


Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Rajiv Agarwal, MD, MS - HIF-PH Inhibitors: An Emerging Strategy for Managing Anemia in Patients With Chronic Kidney Disease

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jun 25, 2021 71:19


Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
Rajiv Agarwal, MD, MS - HIF-PH Inhibitors: An Emerging Strategy for Managing Anemia in Patients With Chronic Kidney Disease

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 25, 2021 70:29


Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
Rajiv Agarwal, MD, MS - HIF-PH Inhibitors: An Emerging Strategy for Managing Anemia in Patients With Chronic Kidney Disease

PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 25, 2021 71:19


Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Rajiv Agarwal, MD, MS - HIF-PH Inhibitors: An Emerging Strategy for Managing Anemia in Patients With Chronic Kidney Disease

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 25, 2021 70:29


Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Rajiv Agarwal, MD, MS - HIF-PH Inhibitors: An Emerging Strategy for Managing Anemia in Patients With Chronic Kidney Disease

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 25, 2021 71:19


Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Rajiv Agarwal, MD, MS - HIF-PH Inhibitors: An Emerging Strategy for Managing Anemia in Patients With Chronic Kidney Disease

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 25, 2021 70:29


Go online to PeerView.com/TWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live web broadcast, experts on anemia management in chronic kidney disease (CKD) highlight the latest evidence for HIF-PH inhibitors and provide expert guidance on integrating these advances into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Review the prevalence, burden, and pathophysiology associated with anemia among patients with CKD, Identify the benefits and limitations of current therapeutic strategies to manage anemia associated with CKD, Assess the safety and efficacy data of HIF-PH inhibitors in patients with anemia in dialysis-dependent (DD)-CKD or nondialysis-dependent (NDD)-CKD, Personalize treatment of anemia in patients with CKD in accordance with current evidence, expert recommendations, and individual patient needs.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Jay B. Wish, MD - Targeting Hypoxia-Inducible Factor Stabilization as a Treatment for Anemia in Chronic Kidney Disease: Examining the Current State of the Science

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 17, 2021 33:55


Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Jay B. Wish, MD - Targeting Hypoxia-Inducible Factor Stabilization as a Treatment for Anemia in Chronic Kidney Disease: Examining the Current State of the Science

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later May 17, 2021 33:58


Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Jay B. Wish, MD - Targeting Hypoxia-Inducible Factor Stabilization as a Treatment for Anemia in Chronic Kidney Disease: Examining the Current State of the Science

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

Play Episode Listen Later May 17, 2021 33:58


Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Jay B. Wish, MD - Targeting Hypoxia-Inducible Factor Stabilization as a Treatment for Anemia in Chronic Kidney Disease: Examining the Current State of the Science

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later May 17, 2021 33:58


Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Jay B. Wish, MD - Targeting Hypoxia-Inducible Factor Stabilization as a Treatment for Anemia in Chronic Kidney Disease: Examining the Current State of the Science

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 17, 2021 33:55


Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Jay B. Wish, MD - Targeting Hypoxia-Inducible Factor Stabilization as a Treatment for Anemia in Chronic Kidney Disease: Examining the Current State of the Science

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later May 17, 2021 33:58


Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Jay B. Wish, MD - Targeting Hypoxia-Inducible Factor Stabilization as a Treatment for Anemia in Chronic Kidney Disease: Examining the Current State of the Science

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later May 17, 2021 33:58


Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
Jay B. Wish, MD - Targeting Hypoxia-Inducible Factor Stabilization as a Treatment for Anemia in Chronic Kidney Disease: Examining the Current State of the Science

PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast

Play Episode Listen Later May 17, 2021 33:58


Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Jay B. Wish, MD - Targeting Hypoxia-Inducible Factor Stabilization as a Treatment for Anemia in Chronic Kidney Disease: Examining the Current State of the Science

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 17, 2021 33:55


Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
Jay B. Wish, MD - Targeting Hypoxia-Inducible Factor Stabilization as a Treatment for Anemia in Chronic Kidney Disease: Examining the Current State of the Science

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 17, 2021 33:55


Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Jay B. Wish, MD - Targeting Hypoxia-Inducible Factor Stabilization as a Treatment for Anemia in Chronic Kidney Disease: Examining the Current State of the Science

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 17, 2021 33:55


Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Jay B. Wish, MD - Targeting Hypoxia-Inducible Factor Stabilization as a Treatment for Anemia in Chronic Kidney Disease: Examining the Current State of the Science

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later May 17, 2021 33:58


Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Jay B. Wish, MD - Targeting Hypoxia-Inducible Factor Stabilization as a Treatment for Anemia in Chronic Kidney Disease: Examining the Current State of the Science

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 17, 2021 33:55


Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Jay B. Wish, MD - Targeting Hypoxia-Inducible Factor Stabilization as a Treatment for Anemia in Chronic Kidney Disease: Examining the Current State of the Science

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later May 17, 2021 33:55


Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.